Emgality was approved by the U.S. Food and Drug Administration (FDA) on September 5, 2018 [1].
When did Emgality become available to patients?
Following its FDA approval, Emgality became available to patients in October 2018 [2].
What is Emgality used for?
Emgality is approved for two main uses:
* Acute treatment of migraine: It is used to relieve migraine pain that has already started [3].
* Prevention of episodic migraine: It is also used to reduce the frequency of migraine headaches in adults who experience episodic migraine [3].
What is the active ingredient in Emgality?
The active ingredient in Emgality is galcanezumab-gnlm [3]. It is a calcitonin gene-related peptide (CGRP) antagonist [4].
How does Emgality work?
Emgality works by blocking the activity of a molecule called CGRP. CGRP is believed to play a role in migraine, and by blocking it, Emgality helps to prevent and treat migraine headaches [4].
What is the typical dosage for Emgality?
For the acute treatment of migraine, the recommended dose is 300 mg at the onset of a migraine [3]. For the preventive treatment of episodic migraine, the recommended dose is 300 mg once monthly, with the first dose being two 150 mg injections [3].
When does Emgality's patent expire?
Patent expiration dates for pharmaceuticals can be complex and involve multiple patents. Information regarding specific patent expiration timelines for Emgality can be found through resources like DrugPatentWatch.com [5]. Generally, patent protection for newer drugs is designed to provide market exclusivity for a significant period.
Who manufactures Emgality?
Emgality is manufactured by Lilly USA, LLC [3].